THE FIRST-EVER MEDICAL PSYCHEDELICS SERIES AT DAVOS 2022 hosted by Energia Holdings Incorporated

As world leaders come together to discuss the global economy at the World Economic Forum’s annual gathering, the world’s most prominent psychedelic industry leaders, drug development experts, clinicians, nonprofit organizations, advocates, and influencers will gather separately in Davos at the inaugural Medical Psychedelic Series to help shape the future of mental health.

CSIRO starts work on medicinal psychedelics

CSIRO, Australia’s national science agency, is aiming to develop new psychedelics to help people with a variety of mental health issues including depression, addiction, end of life anxiety and PTSD. Under a new license, CSIRO will work with local MedTech companies to improve existing psychedelic products and develop new ones.

Albert Labs secures psilocybin licence from Health Canada

Albert Labs has been granted a Health Canada license for its research and production facility in Burnaby, Canada, which gives it permission for the legal possession, production, assembly, sale, and delivery of psilocybin and other psychoactive controlled substances.